[Pharmacodynamic study on the effectiveness of UFT against cancer of gastro-intestinal (GI) tract].
Preoperative oral administration of either 5-FU 200 mg/day (15 patients) or UFT (tegafur plus uracil at a 1:4 molar ratio) 400 mg/day (22 patients) were carried out was carried out against the patients cancer of GI-tract 3 consecutive days till the morning of the operation. Serial blood samples of peripheral and portal veins were obtained for the measurement of concentration of 5-FU. The Concentration of 5-FU in normal and tumor tissues was measured in 13 patients given UFT pre-operatively. Thymidylate synthase inhibition rate were also measured in 5 of them. Furthermore, AgNOR count of tumor tissue before and after administration of UFT were examined in 11 patients. Following conclusions were obtained. (1) The Concentration of 5-FU in peripheral venous blood of UFT group was significantly higher than that of 5-FU group during 1-5 hrs after the last dose (p < 0.05). (2) The concentration of 5-FU in portal venous blood of 5-FU group was higher than that of UFT group during initial 2 hrs after the last dose. However, during 3 to 7 hrs after the last dose, UFT group showed a higher concentration. (3) In UFT group, the concentration of 5-FU in tumor tissue was significantly higher than that in normal tissue (p < 0.01). Consequently, preoperative administration of UFT can be effective for prevention of intraoperative prevention of hematogenous metastasis via portal system in cancer of gastrointestinal tract.
Dept. of Gastroenterological Surgery, National Kyusyu Cancer Center Hospital.
Y
Y
Seo
H
H
Matsuoka
Y
Y
Kakeji
M
M
Morita
S
S
Ohno
A
A
Matsukuma
H
H
Tomoda
M
M
Furusawa
D000284:Administration, Oral; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D002452:Cell Count; D005472:Fluorouracil / Q000097:blood / Q000627:therapeutic use; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D009697:Nucleolus Organizer Region / Q000187:drug effects; D005641:Tegafur / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D014498:Uracil / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use
D005641:Tegafur; D014498:Uracil; D005472:Fluorouracil